E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Marine Anti-inflammatory Agents"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 30 June 2018

Special Issue Editors

Guest Editor
Prof. Elena Talero

Pharmacology, Universidad de Sevilla, Sevilla, Spain
Website | E-Mail
Interests: peptides; natural products; inflammation; inflammatory bowel disease; colon cancer; inflammatory skin diseases
Guest Editor
Dr. Javier Avila

Pharmacology, Universidad de Sevilla, Sevilla, Spain
Website | E-Mail
Interests: microalgae; inflammation; oxylipins; inflammatory bowel disease; colon cancer; inflammatory skin diseases

Special Issue Information

Dear Colleagues,

Acute inflammation is a highly-regulated process, and its dysregulation can lead to the development of a chronic inflammatory state, which is believed to play a main role in the pathogenesis of many diseases, including cancer. The molecular mechanisms underlying chronic inflammation are beginning to be elucidated: Reactive oxygen species (ROS) stimulate intracellular signaling pathways and transcription factors, including MAPK and NF-kB. ROS can also activate a multiprotein complex called inflammasome, which regulates the activation of caspase-1 and subsequent maturation of pro-inflammatory cytokines (IL-1β and IL-18). The transcription factor Nrf2 plays a key role in the protection against oxidative stress in numerous inflammatory diseases since it regulates the transcription of antioxidant enzymes. Moreover, the participation of sirtuins, such as SIRT1 and SIRT6 and autophagy in this process is currently being studied.

In recent years, the need to find new anti-inflammatory molecules has raised the scientific community´s interest for marine natural products. In this regard, the marine environment represents an excellent source to isolate bioactive compounds from microbes, such as bacteria, cyanobacteria, fungi, algae or small invertebrates, such as sponges, tunicates, bryozoans and mollusks. This Special Issue of Marine Drugs will cover the entire scope of marine agents with anti-inflammatory activities, both in vitro and in vivo, as well as the latest status of clinical development from drug trials. In particular, works that evaluate molecular mechanisms of these compounds are especially encouraged.

Prof.  Elena Talero
Dr. Javier Avila
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine compounds
  • Antioxidant molecules
  • Inflammation
  • Immune response
  • Sirtuins
  • Autophagy
  • Inflammasome
  • Cytokines

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Anti-Inflammatory Effects of a Mytilus coruscus α-d-Glucan (MP-A) in Activated Macrophage Cells via TLR4/NF-κB/MAPK Pathway Inhibition
Mar. Drugs 2017, 15(9), 294; doi:10.3390/md15090294
Received: 25 July 2017 / Revised: 3 September 2017 / Accepted: 15 September 2017 / Published: 20 September 2017
PDF Full-text (3808 KB) | HTML Full-text | XML Full-text
Abstract
The hard-shelled mussel (Mytilus coruscus) has been used as Chinese traditional medicine for thousands of years; however, to date the ingredients responsible for the various beneficial health outcomes attributed to Mytilus coruscus are still unclear. An α-d-Glucan, called MP-A,
[...] Read more.
The hard-shelled mussel (Mytilus coruscus) has been used as Chinese traditional medicine for thousands of years; however, to date the ingredients responsible for the various beneficial health outcomes attributed to Mytilus coruscus are still unclear. An α-d-Glucan, called MP-A, was isolated from Mytilus coruscus, and observed to exert anti-inflammatory activity in THP-1 human macrophage cells. Specifically, we showed that MP-A treatment inhibited the production of inflammatory markers, including TNF-α, NO, and PGE2, inducible NOS (iNOS), and cyclooxygenase-2 (COX-2), in LPS-activated THP-1 cells. It was also shown to enhance phagocytosis in the analyzed cells, but to severely inhibit the phosphorylation of mitogen-activated protein kinases (MAPKs) and the nuclear translocation of NF-κB P65. Finally, MP-A was found to exhibit a high binding affinity for the cell surface receptor TLR4, but a low affinity for TLR2 and dectin-1, via surface plasmon resonance (SPR) analysis. The study indicates that MP-A suppresses LPS-induced TNF-α, NO and PEG2 production via TLR4/NF-κB/MAPK pathway inhibition, and suggests that MP-A may be a promising therapeutic candidate for diseases associated with TNF-α, NO, and/or PEG2 overproduction. Full article
(This article belongs to the Special Issue Marine Anti-inflammatory Agents)
Figures

Figure 1

Journal Contact

MDPI AG
Marine Drugs Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: 
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Special Issue Edit a special issue Review for Marine Drugs
logo
loading...
Back to Top